Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA (Q33385353)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA |
scientific article |
Statements
1 reference
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA (English)
1 reference
Vincent Ribrag
1 reference
Christian Gisselbrecht
1 reference
Gilles Salles
1 reference
Jean-Baptiste Golfier
1 reference
Marjan Ertault
1 reference
Christophe Ferme
1 reference
Josette Briere
1 reference
Pauline Brice
1 reference
Nicolas Mounier
1 reference
1 October 2009
1 reference
1 reference
115
1 reference
19
1 reference
4540-4546
1 reference
Identifiers
1 reference
1 reference